{
    "nctId": "NCT00450515",
    "briefTitle": "Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer",
    "officialTitle": "Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Confirmed tumor response",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer meeting the following criteria:\n\n  * Metastatic disease\n  * Previously treated with 1-2 chemotherapy regimens for metastatic disease\n* Measurable disease, defined as \u2265 1 measurable lesion \u2265 2.0 cm by conventional techniques OR \u2265 1.0 cm by spiral CT scan\n\n  * No nonmeasurable disease, including any of the following:\n\n    * Bone lesions\n    * Leptomeningeal disease\n    * Ascites\n    * Pleural or pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Abdominal masses not confirmed and followed by imaging techniques\n    * Cystic lesions\n* Must have received \u2265 1 prior trastuzumab (Herceptin\u00ae)-containing regimen (unless there is a contraindication) if tumor is HER2 positive (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization \\[FISH\\])\n* No CNS metastasis unless controlled by prior surgery and/or radiotherapy\n\n  * \"Controlled\" is defined as \u2265 2 months of no symptoms or evidence of progression\n* Currently enrolled on clinical trial QOL N0392\n* Hormone receptor status not specified\n\n  * Hormone-positive tumor must meet at least 1 of the following criteria:\n\n    * Tumor refractory to hormonal therapy\n    * Heavy visceral tumor burden that requires chemotherapy for better and faster control of metastatic disease\n    * Relapsed disease during adjuvant hormonal therapy and failed first-line chemotherapy\n    * Not treated with hormonal therapy because of side effects or adverse events\n\nPATIENT CHARACTERISTICS:\n\n* Male or female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 3 months\n* Platelet count \u2265 100,000/mm\\^3\n* Hemoglobin \\> 8.0 g/dL\n* WBC \u2265 3,000/mm\\^3\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:\n\n  * AP normal AND AST and ALT \u2264 5 times ULN\n  * AP \u2264 2.5 times ULN AND AST and ALT \u2264 1.5 times ULN\n  * AP \u2264 5 times ULN AND AST and ALT normal\n* Creatinine clearance \u2265 30 mL/min\n* Serum sodium normal\n* Not pregnant or nursing\n\n  * No nursing during and for 30 days after completion of study therapy\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 30 days after completion of study therapy\n* No history of allergy or hypersensitivity to drug product excipients or to agents chemically similar to vinflunine and/or capecitabine\n* No prior unanticipated severe reaction to fluoropyrimidine therapy\n* No known hypersensitivity to fluorouracil\n* No known dihydropyrimidine dehydrogenase deficiency\n* No active, unresolved infection\n* No New York Heart Association class III-IV cardiovascular disease, unstable angina, myocardial infarction within the past 6 months, or poorly controlled hypertension\n* No preexisting neuropathy \u2265 grade 2\n* No concurrent serious medical condition that would preclude study treatment\n* No other stage III or IV invasive cancer within the past 3 years\n* No lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medication\n* Ability to complete questionnaires alone or with assistance\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior unlimited hormonal therapy allowed in the neoadjuvant, adjuvant, or metastatic setting\n* No major surgery, chemotherapy, or immunologic therapy within the past 4 weeks\n* No radiotherapy within the past 4 weeks, except if to a nontarget lesion only\n\n  * Prior radiotherapy to a target lesion is allowed if there has been clear progression of the lesion since radiotherapy was completed\n  * If patient received single-dose radiotherapy or palliation to a nontarget lesion only, the patient may immediately proceed to study registration without waiting 4 weeks\n* No prior fluoropyrimidines, including capecitabine, or vinca alkaloids (e.g., vinorelbine, vinblastine, vincristine, or vindesine) for metastatic breast cancer\n* No prior radiotherapy to \\> 30% of bone marrow-containing areas\n* No cimetidine, allopurinol, sorivudine, or brivudine within the past 2 weeks\n* No ketoconazole, itraconazole, ritonavir, amprenavir, or indinavir within the past 2 weeks\n* No concurrent treatment in another clinical trial in which investigational procedures are performed or investigational therapies are administered\n* No concurrent trastuzumab (Herceptin\u00ae)\n* No concurrent hormonal therapy\n* No concurrent interleukin-11\n* No other concurrent chemotherapeutic agents, biologic agents, or radiotherapy\n* No concurrent administration of any of the following:\n\n  * Cimetidine\n  * Allopurinol\n  * Sorivudine\n  * Brivudine\n  * Ketoconazole\n  * Itraconazole\n  * Ritonavir\n  * Amprenavir\n  * Indinavir\n* Warfarin allowed if patient is on a stable dose and has an INR \\< 3.0",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}